Live Breaking News & Updates on தேர்ந்தெடுக்கப்பட்ட தடுப்பான் ஆஃப் அணு ஏற்றுமதி

Stay updated with breaking news from தேர்ந்தெடுக்கப்பட்ட தடுப்பான் ஆஃப் அணு ஏற்றுமதி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

South Korea , Soult Ukpyolsi , United States , Asia Pacific , Minyoung Kim , Selective Inhibitor Of Nuclear Export , Korean Ministry Of Food , Antengene Corporation , Antengene Corporation Limited , National Comprehensive Cancer Network , South Korean Ministry , Drug Safety , New Drug Application , Orphan Drug Designated , Orphan Drug Designation , North America , General Manager , Selective Inhibitor , Nuclear Export , Corporation Limited , Asia Pacific Region , Patients Beyond , தெற்கு கொரியா , ஒன்றுபட்டது மாநிலங்களில் , ஆசியா பெஸிஃபிக் , தேர்ந்தெடுக்கப்பட்ட தடுப்பான் ஆஃப் அணு ஏற்றுமதி ,

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting
News provided by
Share this article
Share this article
NEWTON, Mass., May 19, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that sixteen abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4-8, 2021.
Key abstracts to be presented at the meeting will feature clinical data for XPOVIO® (selinexor), the Company s first in class, oral Selective Inhibitor of Nuclear Export (SINE) compound, including: (i) multiple new subgroup analyses from the pivotal Phase 3 BOSTON study, including data results evaluating XPOVIO treatment for patients over the age of 65 years old and patients with RAS-mutated mul ....

United States , University Hospital , Xavier Leleu , Christopherj Walker , Mike Dolph , Talia Golan , Shannon Westin , Sangmin Lee , Yasaman Demastani , Cesar Serrano , Darrell White , Cristina Gasparetto , Thierry Facon , Yazmin Odia , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Virginia University School Of Medicine Neurology Neurosurgery , American Society Of Clinical Oncology , Weill Cornell Medical College , Selective Inhibitor Of Nuclear , University Hospitals Leuven , Leuven Cancer Institute , Miami Cancer Institute , Karyopharm Selective Inhibitor Of Nuclear Export , Mcgill University , Information Department ,

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , University Hospital , Xavier Leleu , Christopherj Walker , Mike Dolph , Talia Golan , Shannon Westin , Sangmin Lee , Yasaman Demastani , Cesar Serrano , Darrell White , Cristina Gasparetto , Thierry Facon , Yazmin Odia , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Virginia University School Of Medicine Neurology Neurosurgery , American Society Of Clinical Oncology , Weill Cornell Medical College , Selective Inhibitor Of Nuclear , University Hospitals Leuven , Leuven Cancer Institute , Miami Cancer Institute , Karyopharm Selective Inhibitor Of Nuclear Export , Mcgill University , Information Department ,

Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
Total Revenues of $23.3 Million for the First Quarter of 2021; XPOVIO® (selinexor) Net Product Sales of $21.7 Million
Conditional Marketing Authorization Granted by the European Commission for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma; European Decision for Expanded Multiple Myeloma Indication Expected in the Fourth Quarter of 2021
Richard Paulson Appointed Next President and Chief Executive Officer of Karyopharm
Conference Call Scheduled for Today at 8:30 a.m. ET
News provided by
Share this article
Share this article
NEWTON, Mass., May 3, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021. In addition, Karyopharm highlighted select corporate milestones, including ....

United States , Michaelg Kauffman , Richard Paulson , Sharon Shacham , Selective Inhibitor Of Nuclear Export , American Society Of Clinical Oncology , Takeda Pharmaceutical Company , Karyopharm Selective Inhibitor Of Nuclear Export , European Union , Committee For Medicinal Products Human Use , Information Department , Karyopharm Therapeutics Inc , Drug Administration , European Commission , Progress Towards The International Expansion , Exchange Commission , Ipsen Pharmaceuticals Inc , Development For Solid Tumors , European Medicines Agency , European Commission Ec Grants Conditional Marketing Authorization , Israeli Ministry Of Health , Karyopharm Therapeutics , Chief Executive Officer , Paulson Named Next President , Executive Vice President , Ipsen Pharmaceuticals ,

Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO®

Published: Apr 26, 2021

NEWTON, Mass., April 26, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Company s Type II Variation Marketing Authorization Application (MAA), which seeks to expand the currently authorized indication for NEXPOVIO® in the European Union to include, in combination with Velcade® (bortezomib) and low-dose dexamethasone, the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Validation of the application confirms the submission is complete to begin the EMA s review process. The MAA is supported by the positive results from the pivotal Phase 3 BOSTON study, which evaluated once-weekly selinexor in combination with once-weekly Velcade® and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade® plus low-dose dexam ....

United States , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Karyopharm Therapeutics Inc , World Health Organization , European Commission , Drug Administration , Takeda Pharmaceutical Company , Company Type Ii Variation Marketing Authorization Application , Prnewswire Karyopharm Therapeutics Inc , Exchange Commission , European Union , Karyopharm Selective Inhibitor Of Nuclear Export , European Medicines Agency , Committee For Medicinal Products Human Use , Marketing Authorization Application , Chief Scientific Officer , Medicinal Products , Human Use , Multiple Myeloma , Selective Inhibitor , Nuclear Export , Product Characteristics , Private Securities Litigation Reform Act , Annual Report , Karyopharm Therapeutics ,